Chameleon Science

Chameleon Biosciences is a biotechnology company pioneering a novel approach to gene therapy through its proprietary EVADE (Enveloped Vector Array for Delivery and Evasion) platform. By "cloaking" Adeno-Associated Virus (AAV) vectors with a lipid membrane and human immunomodulatory proteins, the company aims to overcome the primary limitations of current gene therapies, such as pre-existing immunity and the inability to re-dose. Their lead programs, CB-001 and CB-002, are designed to treat Hemophilia B and Hemophilia A, respectively, by providing a safer and more durable therapeutic option. The company's technology has the potential to expand the treatable patient population for gene therapies across various rare genetic disorders.